Clinical Lessons to Be Learned from Patients Developing Chronic Myeloid Leukemia While on Immunosuppressive Therapy after Solid Organ Transplantation: Yet Another Case after Orthotopic Heart Transplantation

Table 1

Currently published case reports of CML developing after solid organ transplantation.

Reference	Age (years)	Sex	Immunosuppression	Latency (mo)	Best response to TKI	Time to best response (mo)	WBC/L	Comment
Cases of kidney transplantation
Battin et al., 1976 [4]	15	m	A	48	—	—	—
Adler et al., 1978 [5]	18	m	A, S, R	32	—	—	—
Lubynski et al., 1978 [6]	20	m	A, S	35	—	—	69.000
Mooy et al., 1978 [7]	40	m	A, S, Actinomycin C	48	—	—	—
Hilario et al., 1980 [8]	26	f	A, S	60	—	—	—
Kirchner et al., 1983 [9]	31	f	A, S, R	42	—	—	73.000	Retransplantation
Sanz et al., 1996 [11]	59	m	A	72	—	—	—
Stein et al., 1978 [12]	19	m	A, S	18	—	—	—
Mignozzi and Picca, 2001 [13]	16	m	A, OKT-3, C, S	96	—	—	65.000
Pescovitz et al., 1996 [14]	52	m	A, ALG, S, C	0	—	—	14.700
Penn, 1998 [15]	Child	—	A, OKT-3	—	—	—	—
Pelloso et al., 2005 [16]	37	m	A, C, S	30	—	—	92.000
Koca et al., 2005 [17]	33	m	A, S, C	87	Imatinib/CCyR	—	—
Thierry et al., 2007 [19]	53	f	ATG, C, M, S	25	Imatinib/MR4	8	28.600
Fontana et al., 2008 [20]	54	f	T, S, M	63	Imatinib/CHR	2	87.540
le Coutre et al., 2010 [21]	39	m	T, C	38	Imatinib/NA	NA	41.300
le Coutre et al., 2010 [21]	47	f	T, C, S	183	Nilotinib/CCyR	NA	27.700	Retransplantation
le Coutre et al., 2010 [21]	54	f	C, M, S	11	NA	NA	139.000
Castillo-Rama et al., 2009 [22]	48	m	A, S, C, M	204	Imatinib/MR4	60	34.500	Retransplantation
Sayar et al., 2011 [23]	18	m	ATG, S, M, T	13	Imatinib/HR	0,5	37.000
Sayar et al., 2011 [23]	56	m	ATG, S, M, T	10	Imatinib/HR	NA	39.000
Oskuei et al., 2014 [25]	63	m	C, M, S	26	Imatinib/CHR	2	59.000
Dhanarajan et al., 2014 [26]	59	m	Sirolimus	120	Imatinib/CCyR	6	NA
Dhanarajan et al., 2014 [26]	77	f	S, T, M	12	Imatinib/HR	1	NA
Dhanarajan et al., 2014 [26]	48	f	S, T	72	Imatinib/CCyR	6	NA	Combined kidney pancreas transplantation
Cases of liver transplantation
Fontana et al., 2008 [20]	55	m	T, S	64	Imatinib/CHR	3	6.200
Fontana et al., 2008 [20]	59	f	T, S	ca. 18	Imatinib/CHR	6	84.600
le Coutre et al., 2010 [21]	63	m	T	32	Imatinib/CCyR	4	37.700
Dhanarajan et al., 2014 [26]	52	m	S, T	48	Imatinib/MR4	18	NA
Cases of lung transplantation
Dhanarajan et al., 2014 [26]	50	m	S, T, A	18	Imatinib/MR4	22	NA
Cases of heart transplantation
Frist and Biggs. 1994 [10]	31	m	A, C, OKT-3, S, R	84	—	—	—	Retransplantation
Sbenghe et al., 2011 [24]	54	m	T, M	14	Imatinib/NA	NA	68.000
Menon et al., 2014 [27]	4	f	T, M	9	Dasatinib/NA	NA	77.700	Secondary CML after AML
Present case	63	m	C, M, S	16	Imatinib/CCyR	15	33.000

A, azathioprine; C, cyclosporine A; S, steroids; ATG/ALG, antithymocyte globulin/antilymphocyte globulin; M, mycophenolate mofetil; T, tacrolimus; R, radiation; NA, not available; WBC: white blood cell count at diagnosis. Retransplantation: several transplantations of the same organ were performed sequentially. Modified according to le Coutre et al. [21].